Spondyloarthritis & psoriatic arthritis
Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study
Main finding · Incident PsA, first-line biologic therapyResult — go to the resultHazard ratio 0.13 95% CI 0.02–0.96Authors' conclusion
IL-17 inhibitor therapy was significantly associated with a reduced risk of incident PsA compared with TNF inhibitors.
Study context
- Population
- Patients with psoriasis initiating biologic therapy between 2002 and 20221,246 received second-line biologics
- Participants
- 2,819 patients
- Exposure
- Biologic classes vs Tumor Necrosis Factor (TNF) inhibitors, first-line and second-line
- Outcome
- Incident PsA
Methodological detailsmultivariable Cox regression, Kaplan-Meier survival analysis
- Multivariable Cox regression
- Kaplan-Meier survival analysis
Main finding
Incident PsA, first-line biologic therapy
Hazard ratio
0.13
95% CI 0.02–0.96
P = 0.045
anti-IL-23p19vs TNF inhibitors
HR 0.13 (95% CI 0.02–0.96); P = 0.045
As reported in the abstract
- Developed psoriatic arthritis (PsA) (first-line cohort)
- 400 (14.2%)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Incident PsA, second-line biologic therapyIL-17 inhibitorsvs TNF inhibitors | 0.37 (0.16–0.85) | P = 0.019 | |
| Incident PsA, second-line biologic therapyanti-IL-12/23vs TNF inhibitors | 0.14 (0.02–1.05) | P = 0.056 | |
| Incident PsA, second-line biologic therapyanti-IL-23p19vs TNF inhibitors | 0.46 (0.20–1.07) | P = 0.070 | |
| 0.050.21520Hazard ratio (log scale) |
- Incident PsA, second-line biologic therapy — Developed PsA (second-line cohort)
- 125 (10.0%)
Original publication
Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study. RMD Open. Published 7 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →